India's Zydus, Lupin sign deal to co-market Semaglutide injections [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
Semaglutide is a GLP-1 ?receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping regulate blood sugar and appetite. The upcoming patent expiry for semaglutide has ?triggered a rush among ?Indian drugmakers to develop cheaper versions to capture market share in the world's most ?populous nation, which has the second-highest number of adults with diabetes after China. Here are some key details: * ?Lupin will ?have semi-exclusive rights to ?co-market Zydus'injection under the ?brand names Semanext and Lupin's Livarise. * Lupin will pay Zydus upfront licensing fees andmilestone-based payments. * Zydus will manufacture the product at its Ahmedabadfacility in Gujarat, and market the product under the brandnames Semaglyntm, Mashematm And ?Alterme. * Unlike existing treatments that ?require multiplesingle-use pens, Zydus' single-adjustable ?pen will allowpatients select ?different doses, lowering costs. * In January, ?Zydus received approval fr
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Strait of Hormuz standoff puts supply of America's generic drug prescriptions at risk [MSNBC.com]MSNBC.com
- India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Ticagrelor Market Size to Reach USD 3.60 Billion by 2035, Fueled by Rising Cardiovascular Disease Burden and Growing Adoption of Advanced Antiplatelet Therapies – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Prolonged Strait of Hormuz standoff will close in on America's generic drug prescriptions [CNBC]CNBC
RDY
Earnings
- 1/22/26 - Beat
RDY
Sec Filings
- 3/13/26 - Form 6-K
- 3/12/26 - Form 6-K
- 3/12/26 - Form 6-K
- RDY's page on the SEC website